



**Sociedad Argentina de
Terapia Radiante Oncológica**

VII Best of ASTRO PROGRAMA



SCIENCE OF TODAY
HOPE FOR TOMORROW

Argentina

4 y 5 de Mayo de 2023

**Hotel Meliã - Reconquista 945
CABA - Argentina**



SCIENCE OF TODAY
HOPE FOR TOMORROW

Argentina

Este evento se realiza con licencia de American Society for Radiation Oncology “ASTRO” con el objetivo de difundir los trabajos con mejor puntuación del ASTRO Annual Meeting del año 2022, Octubre 23 - 26, en San Antonio, Texas, USA

Comisión Directiva 2022 - 2024



Presidente

Dra. Verónica Vázquez Balcarce

Vicepresidente

Dr. Jorge Palazzo

Secretario General

Dr. José Máximo Barros

Secretario de Actas

Dr. Ignacio Sisamón

Prosecretaria

Dra. Vanesa Krakobsky

Tesorera

Dra. Patricia Bruno

Protesorero

Dr. Oscar Gómez Orrego

Vocales Titulares

Dra. Luisa Rafailovici

Dr. Lucas Causa

Dra. Cecilia Coll

Dra. Claudia De Angelis

Dr. Marcelo Andrade Irusta

Dr. Carlos Donoso

Vocales Suplentes

Dr. Javier Otero

Dr. Mauro Mattio

Dra. María José Girola

Dra. Luz Font

Dr. Juan Galarraga

Dr. Federico Díaz

Dra. Beatriz Mazza

Órgano de Fiscalización

Revisores de Cuentas Titulares

Dr. Emilio Astiz

Dr. Augusto Alva

Revisores de Cuentas Suplentes

Dra. Mara Scarabino

Dr. José Alejandro Capraro

Comité de Ética

Dra. Ana Mabel Martínez

Dra. Estela Broda

Dr. Ricardo Alva

Dr. Hugo Donato

Comité Científico

Dra. Luisa Rafailovici

Dra. María Luisa Filomia

Dra. Mabel Sardi

Dr. Carlos Cardiello

Comité Editorial

Dra. Carolina Chacón

Dra. Carmen Castro

Información General

Secretaría SATRO:

Sra. Rosario Val

Cel / Whatsapp: +54911 6369-6348

e-mail: xina_arg@hotmail.com

Sitio web: www.sat-ro-radioterapia.com.ar

Facebook: Sociedad Argentina de Terapia Radiante Oncologic

Instagram: socterapiaradiante

YouTube: Satro Radioterapia

Linkedin: [linkedin.com/in/rosario-val-77446920](https://www.linkedin.com/in/rosario-val-77446920)

Secretaría Evento:

IV Eventos – Lic. Inés Vuoto

Cel / Whatsapp: +54911 5035-0701

e-mail: ines@iveventos.com

Agradecemos a las Siguietes Empresas

SPONSORS DIAMANTE

varian

A Siemens Healthineers Company



Photonix

Tecnología Médica e Industrial

Distribuidor Autorizado



positioning
patients for life.®



VIDT
ONCOLOGIA RADIANTE

SPONSORS PLATINO

AstraZeneca 



LINAC
systems S.A.

SPONSOR ORO

INVAP



SUN NUCLEAR
corporation



Photonix

Tecnología Médica e Industrial

Distribuidor exclusivo

Jueves 4 de Mayo

08:00 – 15:30 hs. Acreditación

09:00 – 10:15 hs. Módulo 1: Cáncer de Cabeza y Cuello

09:00 – 09:05 hs. Presidente: Dra. Cecilia Coll,
Instituto Privado de Radioterapia Cuyo, Mendoza
Coordinador: Dr. Diego Fernández, Centro de Radioterapia Dean Funes, Córdoba

Disertantes:

09:05 – 09:15 hs. Dr. Jorge Palazzo, Vidt Centro Médico, Tucumán

Abstract 70: Patient Reported Outcomes (PROs) in MC1675, De-escalated Adjuvant Radiation Therapy (DART) versus Standard of Care Adjuvant Radiation Therapy (SOC) for HPV Associated Oropharyngeal Squamous Cell Carcinoma

Abstract 73: Long-term Risk of Carotid Stenosis and Cerebrovascular Disease after Radiation Therapy for Head and Neck Cancer

09:15 – 09:25 hs. Dr. Carlos Alberto Cardiello, Vidt Centro Médico, Buenos Aires

Abstract 66: A Phase II Study of Volume and Dose De-Intensification Following Transoral Robotic Surgery (TORS) and Neck Dissection for p16+ Oropharyngeal Squamous Cell Carcinoma

Abstract 72: Reduced aspiration rates for 50 Gy postoperative radiation in HPV-associated oropharynx cancer in E3311: a trial of the ECOG-ACRIN Cancer Research Group

09:25 – 09:35 hs. Dr. Emilio Astiz, CEDITRA, Buenos Aires

Abstract 68: Genomic Adjusted Radiation Dose (GARD) Predicts Overall Survival and Outperforms AJCC 8th Edition in Prognostication of HPV-positive Oropharyngeal Squamous Cell Carcinoma

Abstract 71: ctHPVDNA and Recurrence Risk in MC1675, a secondary analysis of a Phase III Evaluation of De-escalated Adjuvant Radiation Therapy (DART) versus Standard Adjuvant Treatment for HPV Associated Oropharyngeal Squamous Cell Carcinoma

09:35 – 09:45 hs. Dr. Diego Felipe Rincón, Genesis Care, Madrid, España

Abstract 67: Screening for extranodal extension with deep learning: evaluation in ECOG-ACRIN E3311, a randomized de-escalation trial for HPV-associated oropharyngeal carcinoma

Abstract 69: Intra-treatment tumor apparent diffusion coefficient, a quantitative imaging metric, is associated with neck nodal recurrence in de-escalated treatment of HPV-positive oropharyngeal cancer (OPC)

09:45 – 10:15 hs. Mesa de Discusión:

Coordinador: Dr. Diego Fernández(RT)

**Panelistas: Dra. Cecilia Coll (RT), Dr. Jorge Palazzo (RT), Dr. Carlos Cardiello (RT), Dr. Emilio Astiz (RT), Dr. Diego Felipe Rincón (RT)
Dr. Agustín Falco, (Oncología Clínica), Instituto Alexander Fleming, Bs. As.
Dr. Bárbara Berenstein (Cirugía), Universidad del Salvador, Buenos Aires**

Jueves 4 de Mayo

10:15 – 10:30 hs. Inauguración VII Best of ASTRO

Dra. Verónica Vazquez Balcarce

Presidente SATRO

Entrega de Diplomas de Recertificación

10:30 – 11:00 hs. Intervalo Café

Jueves 4 de Mayo

11:00 – 12:00 hs. **Módulo 2: Sarcomas y Tumores Cutáneos**

11:00 – 11:05 hs. **Presidente: Dr. Diego Fernández,**
Centro de Radioterapia Dean Funes, Córdoba

Coordinadora: Dra. Gabriela Genovese,
Hospital Oncológico Dr. José Miguel Urrutia, Córdoba

Disertantes:

11:05 – 11:15 hs. **Dr. Franco Schnitman, UNITER, Paraná, Entre Ríos**

Abstract 138: Prospective Single-arm Trial of preoperative 42.75 Gy in 15 fractions for soft tissue sarcoma of the extremity/trunk

Abstract 139: Thirteen Years with Preoperative 5x5 Gy in Soft Tissue Sarcomas: A Pattern of Local Failure

11:15 – 11:25 hs. **Dra. Ana Martínez, CEDITRIN, Buenos Aires**

Abstract 140: Stereotactic Ablative Radiation Therapy for Sarcoma Lung Metastases: indications for treatment and patterns of failure

Abstract 141: Role of Adjuvant Regional Nodal Irradiation in Resected Melanoma: A Secondary Analysis of SWOG S1404

11:25 – 11:30 hs. **Dr. Gonzalo Mandiola,**
Centro Oncológico de las Sierras, Tandil, Pcia. de Buenos Aires

Abstract 142: Innovative Widefield Volumetric Arc Radiation Therapy (VMAT) Approach to Simultaneously Treat Extensive Skin Field Cancerization (ESFC) + In-field Keratinocyte Carcinoma (KC) in Australian Patients: Report with 12 Month Follow-up.

11:30 – 12:00 hs. Mesa de Discusión:

Coordinadora: Dra. Gabriela Genovese (RT)

Panelistas: Dr. Diego Fernández (RT), Dr. Franco Schnitman (RT),

Dra. Ana Martínez (RT), Gonzalo Mandiola (RT)

Dr. Matías Chacon, **Oncología, Instituto Alexander Fleming, Buenos Aires**

Dr. Marcos Galli Serra, **Ortopedia Oncológica,**
Hospital Universitario Austral, Buenos Aires

Jueves 4 de Mayo

12:00 – 13:15 hs. Módulo 3: Cáncer Pediátrico

12:00 – 12:05 hs. Presidente: Dr. Oscar Gómez Orrego, Consultorio Privado de Radiaciones Gral. San Martín, Buenos Aires

Coordinadora: Dra. Ana Martínez, CEDITRIN, Buenos Aires

Disertantes:

12:05 – 12:20 hs. Dra. Natalia Pinto, Hospital Garrahan, Buenos Aires

Abstract 121: Local Failure in Non-metastatic Ewing Sarcoma Patients Treated with Definitive Radiation Therapy on AEWS1031. A Report from the Children's Oncology Group

Abstract 127: Analysis of local control outcomes and clinical prognostic factors in localized pelvic Ewing sarcoma patients treated with radiation therapy: A Report from the Children's Oncology Group

Abstract 130: Local Control for Large Unresectable Intermediate Risk Pediatric Rhabdomyosarcomas

12:20 – 12:25 hs. Dra. Soledad Colombo, Mevaterapia Oncología Radiante, Buenos Aires

Abstract 128: Volumetric Modulated Arc Therapy Total Body Irradiation (VMAT-TBI) in Pediatric and Adolescent/Young Adult Patients Undergoing Stem Cell Transplantation: Early Outcomes and Toxicities

12:25 – 12:35 hs. Dra. Florencia Variglia y Pons, Hospital Garrahan, Buenos Aires

Abstract 123: Second Neoplasms in Children following Radiotherapy in the Modern Era: A Bicentric Report from the University of Florida and Memorial Sloan Kettering Cancer Center

Abstract 129: Risk of Subsequent Central Nervous System Neoplasms in Childhood Cancer Survivors after Radiation Therapy: Results from the Pediatric Normal Tissue Effects in the Clinic (PENTEC) Collaboration

12:35 – 12:45 hs. Dr. Sergio Quiceno, Vidt Centro Médico, Buenos Aires

Abstract 125: Radiation (RT)-Associated Kidney Injury in Pediatric Cancer Patients: Results from the Pediatric Normal Tissue Effects in the Clinical (PENTEC) genitourinary (GU) task force.

Abstract 126: Retinopathy, Optic Neuropathy, and Cataract in Childhood Cancer Survivors Treated with Radiotherapy: A Report From the Pediatric Normal Tissue Effects in the Clinic (PENTEC) Initiative

12:45 – 13:15 hs. Mesa de Discusión:

Coordinador: Dra. Ana Martínez (RT)

Panelistas: Dr. Oscar Gómez Orrego (RT), Dra. Natalia Pinto (RT), Dr. Sergio Quiceno (RT), Dra. Soledad Colombo (RT), Dra. Florencia Variglia y Pons (RT)
Dra. Blanca Diez, **Neuro-Oncología**, Instituto FLENI, Buenos Aires
Dr. Marcelo Urbietta, **Oncología**, Hospital de Niños "Ricardo Gutierrez", Bs. As.

Jueves 4 de Mayo

13:15 – 13:45 hs. Simposio VARIAN

Dr. Federico Bakal

Fundación Arturo López Pérez, Santiago, Chile

Tema: A Confirmar

13:45 – 15:20 hs. Intervalo Lunch SATRO

Jueves 4 de Mayo

15:20 – 16:35 hs. Módulo 4: Cáncer de Pulmón

15:20 – 15:25 hs. Presidente: Dra. Berta Roth, CEMIC, Buenos Aires
Coordinador: Dr. Claudio Martín, Instituto Alexander Fleming, Bs. As.

Disertantes:

15:25 – 15:35 hs. Dr. Nicolás Isa, Clínica IRAM, Santiago, Chile

Abstract 94: Pembrolizumab plus Concurrent Chemoradiation Therapy (cCRT) for Unresectable, Locally Advanced, Stage III NSCLC: KEYNOTE-799 2-Year Update

Abstract 95: Left Anterior Descending Coronary Artery Radiation Dose Association with All-Cause Mortality in NRG Oncology Trial RTOG 0617

15:35 – 15:45 hs. Dr. Aldo Quarneti, Hospital Pereira Rossell, Montevideo, Uruguay

Abstract 97: Validation of the Prognostic Utility of ESTRO/EORTC Oligometastatic Disease Classification: A Secondary Analysis from the Population-Based Phase II SABR-5 Trial

Abstract 98: iSABR: Safety and Efficacy Results from a Phase II Study of SABR in Combination with Durvalumab for Early-Stage Medically Inoperable NSCLC

15:45 – 15:55 hs. Dr. Alejandro Chinellato, Terapia Radiante Cumbres, Rosario, Sta. Fe

Abstract 99: Comparison of Simultaneous Integrated Boost IMRT for Dose Escalation (54 Gy) and Conventional IMRT (45 Gy) Twice Daily Combined With Concurrent Chemotherapy for Limited-Stage Small-Cell Lung Cancer: Analysis of Two Prospective Trials

Abstract 100: Effect of EGFR-TKIs Combined with Cerebral Radiotherapy on Prognosis of Patients with EGFR-Mutant Lung Adenocarcinoma with Brain Metastasis

15:55 – 16:05 hs. Dra. Andrea Pozo, Hospital Alemán, Buenos Aires

Abstract 101: Predictors of Early Polymetastasis after Comprehensive Local Therapy for Synchronous Oligometastatic NSCLC

Abstract 102: Relationship Between Cardiac Dose and Overall Survival after Radiotherapy in a Large Cohort of Patients with Locally Advanced NSCLC

16:05 – 16:35 hs. Mesa de Discusión:

Coordinador: Dr. Claudio Martín, Oncología Clínica

Panelistas: Dra. Berta Roth (RT), Dr. Nicolas Isa (RT), Dr. Aldo Quarneti (RT),
Dr. Alejandro Chinellato (RT), Dra. Andrea Pozo (RT)
Dr. Felipe Couñago, **Oncología Radioterápica**, Genesis Care, Madrid, España
Dr. Enrique Díaz Cantón, **Oncología Clínica**, CEMIC, Buenos Aires

Jueves 4 de Mayo

16:35 – 17:40 hs. Módulo 5: Cáncer Genitourinario

16:35 – 16:40 hs. Presidente: Dr. Marcelo Andrade Irusta, CEMIC, Buenos Aires

Coordinadora: Dra. Carolina Chacón, Instituto Alexander Fleming, B. A.

Disertantes:

16:40 – 16:50 hs. Dra. Beatriz Mazza, Centro de Radioterapia Gral. San Martín, Bs. As.

Abstract 51: Multi-institutional matched comparison of radical cystectomy to trimodality therapy for muscle invasive bladder cancer (MIBC)

Abstract 54: Bladder Only Versus Bladder Plus Pelvic Lymph Node Chemoradiation for Muscle-Invasive Bladder Cancer

16:50 – 17:00 hs. Dr. Andrés Rodríguez Mignola, Instituto Ángel Roffo, Bs. As.

Abstract 52: PSMA PET/CT–based atlas for prostatic bed recurrence of prostate cancer after radical prostatectomy: clinical implications for salvage radiation therapy

Abstract 53: Long-term Outcomes of SABR to Primary Renal Cell Carcinoma: A Multicenter Analysis from IROCK (International Radiosurgery Oncology Consortium for Kidney)

17:00 – 17:10 hs. Dr. Matías Zapata, Hospital Universitario Austral, Buenos Aires

Abstract 46: Conventional vs Hypofractionated, radiotherapy for high-risk prostate cancer: 7-year outcomes of the randomized, non-inferiority, phase 3 PCS5 trial

Abstract 48: Magnetic resonance imaging-guided versus computed tomography-guided stereotactic body radiotherapy for prostate cancer (MIRAGE): Primary Endpoint Analysis Phase III Randomized Trial

17:10 – 17:40 hs. Mesa de Discusión:

Coordinadora: Dra. Carolina Chacón (RT)

Panelistas: Dr. Marcelo Andrade Irusta (RT), Dra. Beatriz Mazza (RT),
Dr. Andrés Rodríguez Mignola (RT), Dr. Matías Zapata (RT)
Dr. Felipe Couñago, **Oncología Radioterápica**, Genesis Care, Madrid, España
Dr. Gustavo Villoldo, **Urología**, Instituto Alexander Fleming, Buenos Aires
Dr. Federico Losco, **Oncología Clínica**, Instituto Alexander Fleming, Bs. As.
Dra. Olinda Bustos Endara, **Diagnóstico por Imágenes**, TCBA, Buenos Aires

17:40 – 18:10 hs. Intervalo Café

Jueves 4 de Mayo

18:10 – 19:25 hs. Módulo 6: Hematología Oncológica

18:10 – 18:15 hs. Presidente: Dra. Cecilia Barrientos Zuñiga, CEMIC, Buenos Aires

Coordinador: Dr. Juan José Galarraga, Centro de Oncología y Radioterapia, Mar del Plata, Buenos Aires

Disertantes:

18:15 – 18:25 hs. Dr. Luis Carvajal, Centro Médico Dean Funes, La Plata, Buenos Aires

Abstract 74: Response Adapted Ultra Low Dose Radiation Therapy for the Definitive Management of Orbital Indolent B-cell Lymphoma

Abstract 75: Impact of Myc-Altered Pathology on Radiotherapy Efficacy Among Patients with Relapsed/Refractory Large-B Cell Lymphoma: A Collaborative Retrospective Study

18:25 – 18:35 hs. Dr. Miguel Castiglioni, Instituto de Tumores Rosario, Santa Fe

Abstract 76: Comprehensive Salvage Radiotherapy for Limited Relapsed B-cell Non-Hodgkin Lymphoma Following CD19 Chimeric Antigen Receptor T-Cell Therapy

Abstract 77: Outcomes and Failure Patterns for >500 Patients Treated for Primary CNS Lymphoma: Exploring Modern Roles for Radiotherapy

18:35 – 18:45 hs. Dr. Ariel Gómez Palacios, Centro de Radioterapia Dean Funes, Córdoba

Abstract 78: Radiation Therapy for Bridging and Improving CAR-T Cell Therapy

Abstract 79: Patterns of Relapse and Risk Reduction Following Tumor Debulking by Bridging Radiotherapy Prior to Chimeric Antigen Receptor T Cell Therapy in Non-Hodgkin Lymphoma

18:45 – 18:55 hs. Dr. Pablo Converso, Vidt Centro Médico, Buenos Aires

Abstract 80: Outcomes of Salvage Radiotherapy in Refractory or Relapsed High-Grade B-Cell Lymphoma Patients Treated with Commercial CAR T-Cell Therapy

Abstract 81: Patterns of Progression on Immune Checkpoint Inhibitor Therapy for Relapsed Hodgkin Lymphoma: Implications for the Potential Role of Radiation Therapy

18:55 – 19:25 hs. Mesa de Discusión:

Coordinador: Dr. Juan Galarraga (RT)

Panelistas: Dra. Cecilia Barrientos Zuñiga (RT), Dr. Luis Carvajal (RT),
Dr. Miguel Castiglioni (RT), Dr. Ariel Gómez Palacios (RT),
Dr. Pablo Converso (RT)
Dra. Astrid Pavlovsky, Onco-Hematología, Centro Médico FUNDALEU, Bs. As.

Viernes 5 de Mayo

08:30 – 12:30 hs. Acreditación

09:00 – 10:15 Módulo 7: Sistema Nervioso Central

09:00 – 09:05 hs. Presidente: Dr. Ignacio Sisamón,
Centro de Oncología y Radioterapia, Mar del Plata, Buenos Aires

Coordinadores: Dr. Lucas Caussa, Centro de Radioterapia Dean Funes, Córdoba
Dr. José Máximo Barros, Hospital Universitario Austral, Buenos Aires

Disertantes:

09:05 – 09:10 hs. José Capraro, CETAC Juncal, Temperley, Buenos Aires

Abstract 11: Phase II Randomized Trial Comparing Proton Craniospinal Irradiation with Photon Involved-Field Radiotherapy for Patients with Solid Tumor Leptomeningeal Metastasis

09:10 – 09:15 hs. Dr. Diego Gronovich, Hospital Universitario Austral, Buenos Aires

Abstract 12: Evaluating Heterogeneity of Hippocampal Avoidant Whole Brain Radiotherapy (HA-WBRT) Treatment Effect on Neurocognitive Function (NCF): Secondary Analysis of NRG-CC001

09:15 – 09:25 hs. Dr. Leandro Ricagni, Universidad de la República, Montevideo, Uruguay

Abstract 13: Mature Local Control and Reirradiation Rates Comparing Spine Stereotactic Body Radiotherapy to Conventional Palliative External Beam Radiotherapy

Abstract 14: Risk Factors for Progression and Toxicity After Preoperative Radiosurgery for Resected Brain Metastases: A PROPS-BM Multicenter Cohort Study

09:25 – 09:30 hs. Dra. Silvia Hansing, Centro Oncológico Integral “COI”, Neuquén

Abstract 15: Pre-Operative Versus Post-Operative Fractionated Stereotactic Radiotherapy for Patients with Brain Metastases: A Multi-Institutional Analysis

09:30 – 09:35 hs. Dra. Cintia Erica Bertoncini, CEMENER, Entre Ríos

Abstract 16: Stereotactic Body Radiation Therapy for High-Grade Malignant Epidural Spinal Cord Compression from Solid Tumor Metastases

09:35 – 09:45 hs. Dra. Jessica Chávez Noguera, Médica Sur, México

Abstract 19: Beyond the hippocampus: White matter memory network implicated in post-radiation memory decline in primary brain tumor patients

Abstract 20: Predictors of radiation necrosis and dose/volume tolerance of the brain after three-fraction radiosurgery for brain metastases: A large single-institutional analysis

09:45 – 10:15 hs. Mesa de Discusión:

Coordinadores: Dr. Lucas Caussa (RT), Dr. José Máximo Barros (RT)

Panelistas: Dr. Ignacio Sisamón (RT), Dr. José Capraro (RT), Dr. Diego Gronovich (RT),
Dr. Leandro Ricagni (RT), Dra. Silvia Hansing (RT), Dra. Cintia E. Bertoncini (RT),
Dra. Jessica Chávez Noguera (RT)

Dr. Jorge Mandolesi, Neurocirugía, Instituto FLENI, Buenos Aires

Dr. Alejandro Muggeri, Oncología, Instituto FLENI, Buenos Aires

Dr. Kita Sallabanda, Neurocirugía, Instituto de Radiocirugía Avanzada, Madrid, España

Viernes 5 de Mayo

10:15 – 10:45 hs. Sesión Presidencial

**Coordinadora: Dra. Vanesa Krakovsky,
Mevaterapia Oncología Radiante,
Hospital Italiano de Buenos Aires**

10:15 – 10:40 hs. Prof. Dr. Roberto Orecchia



Istituto Europeo di Oncologia, Milan, Italia

Tema: “Inteligencia Artificial y Radioterapia”

10:40 – 10:45 hs. Preguntas

10:45 – 11:15 hs. Intervalo Café

Viernes 5 de Mayo

11:15 – 12:30 hs. Módulo 8: Cáncer de Mama

11:15 – 11:20 hs. **Presidente:** Dra. Patricia Bruno, CEPROR, Villa María, Córdoba

Coordinadora: Dra. Vanesa Krakobsky,

Mevaterapia Oncología Radiante, Hospital Italiano de Buenos Aires

Disertantes:

11:20 – 11:30 hs. **Dra. Luisa Rafailovici, Vidt Centro Médico, Buenos Aires**

Abstract 1: NRG RTOG 1005: A Phase III Trial of Hypo fractionated Whole Breast Irradiation with Concurrent Boost Versus Conventional Whole Breast Irradiation plus Sequential Boost following Lumpectomy for High Risk Early-Stage Breast Cancer

Abstract 10: Re-thinking Clinicopathologic Risk Assessment in DCIS: Pooled Data from Validation Studies Comparing a 7-gene DCIS Assay to Clinicopathologic Features Alone

11:30 – 11:40 hs. **Dra. Ana Díaz Gavela,**

Hospital Universitario Quirónsalud, Madrid, España

Abstract 4: Ultra-accelerated photons, protons, or brachytherapy for favorable early breast cancer: long-term results of a 3-fraction partial breast irradiation trial

Abstract 8: Radiotherapy Use and Locoregional Recurrence Rates on SWOG 1007, a US Cooperative Group Trial Enrolling Patients with Favorable-Risk Node-Positive Breast Cancer

11:40 – 11:50 hs. **Dra. Sofía Sánchez García, Hospital La Luz, Madrid, España**

Abstract 2: Accelerated Partial Breast Irradiation (2021) Using Five Daily Fractions: A Prospective, Phase II, Multi-centre Trial of Cosmetic Outcomes and Toxicity: Final Results

Abstract 3: Physician Rated Cosmesis and Patient Reported outcomes after Concomitant Boost (CB) versus Sequential Boost (SB) for Adjuvant Treatment of Breast Cancer: A Prospective Randomized Study

11:50 – 12:00 hs. **Dr. Enrique Díaz Cantón, CEMIC, Buenos Aires**

Abstract 7: Concurrent Olaparib with radiotherapy in patients with triple negative breast cancer: final results of the RADIOPARP phase 1 trial

Abstract 9: A Phase I Study of Adjuvant Niraparib Administered Concurrently with Postoperative Radiation Therapy in Patients with Localized Triple Negative Breast Cancer

12:00 – 12:30 hs. Mesa de Discusión:

Coordinador: Dra. Vanesa Krakobsky (RT)

Panelistas: Dra. Patricia Bruno (RT), Dra. Luisa Rafailovici (RT), Dra. Ana Díaz Gavela (RT)
Dra. Sofía Sánchez García (RT), Dr. Enrique Díaz Cantón (Oncología Clínica)
Dr. Mario De Romedi (Oncología Clínica), Instituto IMGO, Córdoba
Dra. M. Fernanda Díaz Vázquez (RT), Centro de Radioterapia Dean Funes, Córdoba
Dra. Soledad del Castillo (Cirujana), Instituto IMGO, Córdoba

Viernes 5 de Mayo

12:30 – 13.00 hs. Simposio AstraZeneca

Coordinador: Dr. José Máximo Barros
Hospital Universitario Austral, Buenos Aires

Disertante: Dra. Carmen Rubio
Jefa de Servicio Oncología Radioterápica Hospital
Universitario HM Sanchinarro, Madrid, España
Vicepresidenta de la Sociedad Española de
Oncología Radioterápica

Tema: “*Radioterapia en Cáncer de Pulmón Operable*”

Viernes 5 de Mayo

13:00 – 14:15 hs. Módulo 9: Cáncer Gastrointestinal

13:00 – 13:05 hs. Presidente: Dra. Mabel Sardi,
Mevaterapia Oncología Radiante, Buenos Aires

Coordinadora: Dra. Higinia Cardenes, Weill Cornell University, New York, USA

Disertantes:

13.05 – 13:15 hs. Dra. Mabel Sardi, Mevaterapia Oncología Radiante, Buenos Aires

Abstract 36: Patient-reported Outcomes (PROs) in NRG Oncology RTOG 1010: Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2 Overexpressing (HER2+) Esophageal Adenocarcinoma (EAC)

Abstract 38: Non-operative management is feasible and safe in patients with rectal cancer who achieve clinical complete response to short-course radiation therapy and consolidation chemotherapy

13:15 – 13:25 hs. Dr. Carlos Donoso, CEDITRA, Buenos Aires

Abstract 40: Impact of Lung and Heart Radiation Dose during Preoperative Chemoradiation on Overall Survival (OS) in Esophageal Cancer (EC)–Secondary Analysis of CALGB 80803 (Alliance)

Abstract 43: Concurrent chemoradiation of different doses (50.4 Gy vs. 59.4 Gy) and different target field (ENI versus IFI) for locally advanced esophageal squamous cell carcinoma: results from a randomized, multicenter phase III clinical trial

13:25 – 13:35 hs. Dra. Mariana Galli, Instituto Alexander Fleming, Buenos Aires

Abstract 39: Radiotherapy Enhance the Immune Checkpoint Inhibitors Efficacy in advanced liver cancer

Abstract 45: Liver function preservation and outcome after SBRT with functional treatment planning in patients with HCC and advanced hepatic cirrhosis: from nuclear medicine to MRI-based functional treatment planning platform.

13:35 – 13:45 hs. Dr. Augusto Alva, Mevaterapia Oncología Radiante, Buenos Aires

Abstract 37: Multi-Institutional comparison of ablative RT in 5 versus 15-25 fractions for locally advanced pancreatic cancer

Abstract 41: Radiation Therapy (RT) Quality Assurance (QA) Analysis of Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the pancreas (PDAC)

13:45 – 14:15 hs. Mesa de Discusión:

Coordinadora: Dra. Higinia Cardenes (RT)

Panelistas: Dra. Mabel Sardi (RT), Dr. Carlos Donoso (RT), Dra. Mariana Galli (RT),
Dr. Augusto Alva (RT),
Dr. Eduardo Huertas, **Cirugía**, Instituto Alexander Fleming, Buenos Aires
Dr. Guillermo Mendez, **Oncología**, Fundación Favaloro, Buenos Aires

14:15 – 15:45 hs. Intervalo Almuerzo Libre

Viernes 5 de Mayo

15:45 – 17:00 hs. Módulo 10: Cáncer Ginecológico

15:45 – 15:50 hs. Presidente: Dra. Luciana Brun,

Centro de Radioterapia Dean Funes, Córdoba

Coordinadora: Dra. Higinia Cardenes, Weill Cornell University, New York, USA

Disertantes:

15:50 – 16:00 hs. Dr. Gastón Lemoine, Instituto de Radiaciones, Salta

Abstract 56: A Pilot Study of Moderately Hypo-Fractionated Whole Pelvic Radiotherapy with Concurrent Chemotherapy and Image Guided High Dose Rate Brachytherapy for Locally Advanced Cervical Carcinoma

Abstract 57: Atezolizumab and Stereotactic Body Radiation Therapy in Metastatic, Recurrent, or Persistent Cervical Cancer: Interim Results from a Non-Randomized, Open-Label Phase II Multi-Institutional Study

16:00 – 16:10 hs. Dra. Cecilia Belén Ríos, Centro de Radioterapia Dean Funes, Córdoba

Abstract 62: Definitive High-Dose Radiotherapy for Primary Vulvar Cancer: The DRIVE Multicenter Cohort Study

Abstract 65: Impact of Adjuvant Pelvic External Beam Radiotherapy or Vaginal Brachytherapy on Clinical Outcomes for Early-Stage Uterine Carcinosarcoma

16:10 – 16:20 hs. Dr. José Luis Asís, Centro Oncológico Riojano Integral, La Rioja

Abstract 63: Improved Outcomes with Adjuvant Radiation Therapy in Early-Stage Endometrial Cancer with Abnormal Beta-Catenin Expression

Abstract 64: Single-cell and spatial transcriptomics revealing HPV- cervical cancer tumor microenvironment heterogeneity and implications to Radiation and Immunotherapy

16:20 – 16:25 hs. Dr. Emiliano Lissandrello, Mevaterapia Oncología Radiante, Bs. As.

Abstract 60: The role of circulating tumor cells as potential predictive and prognostic factors in cervical cancers

16:25 – 16:30 hs. Dr. Lucas Staringer, Mevaterapia Oncología Radiante, Bs. As.

Abstract 61: Circulating Cell Free DNA As Predictive Biomarker In Cervical Cancer Patients Treated With Radical Chemo-Radiation

16:30 – 17:00 hs. Mesa de Discusión:

Coordinadora: Dra. Higinia Cardenes (RT)

Panelistas: Dra. Luciana Brun (RT), Dr. Gastón Lemoine (RT), Dra. Cecilia Belén Ríos (RT), Dr. José Luis Asís (RT), Dr. Emiliano Lissandrello (RT), Dr. Lucas Staringer (RT), Dr. Juan Carlos Staringer, **Ginecología Oncológica**, Hosp. Italiano, La Plata, Bs. As. Dr. Gastón Reinas, **Oncología Clínica**, Hospital Rivadavia, Buenos Aires
Dr. Mauricio Luongo, (RT), ClínicaCOR, Montevideo, Uruguay

17:00 – 17:30 hs. *Intervalo Café*

Viernes 5 de Mayo

17:30 – 18:45 hs. Módulo 11: Cuidados Paliativos

Organizado por el Capítulo de Jóvenes Radioncólogos de SATRO

**17:30 – 17:35 hs. Presidente: Dr. Javier Otero, Hospital Universitario Austral, Bs. As.
Coordinadora: Dra. Ofelia Pérez Conci, Centro de Radioterapia Dean Funes, Córdoba**

Disertantes:

17:35 – 17:45 hs. Dr. Afonzo Daza, Instituto Ángel Roffo, Buenos Aires

Abstract 104: Does compromising target coverage impact overall survival when treating Oligometastatic Disease with Stereotactic Ablative Radiotherapy (SABR)?

Abstract 105: Does local failure following oligometastasis-directed SBRT predict for widespread progression and overall survival?

17:45 – 17:55 hs. Dr. Diego Arroyo, Vidt Centro Médico, Buenos Aires

Abstract 106: Stereotactic Body Radiation Therapy versus Conventional External Beam Radiation Therapy for Painful Bone Metastases: A Systematic Review and Meta-analysis of Randomized Trials

Abstract 109: FAST-01: Results of the First-In-Human Study of Proton FLASH Radiotherapy

17:55 – 18:05 hs. Dra. Paola Sánchez, Vidt Centro Médico, Buenos Aires

Abstract 110: Hypofractionated Two Week Short-Course Radiotherapy vs. Monthly Single Fraction Palliative Pelvic Radiation in Advanced Gynaecologic Cancers

Abstract 111: Adverse Events Following Treatment with Combination Ablative Radiotherapy and Immunotherapy: A Pooled Analysis of Phase I Trials

18:05 – 18:15 hs. Dr. Afonzo Daza, Instituto Ángel Roffo, Buenos Aires

Abstract 112: Population Based Phase II Trial of Stereotactic Ablative Radiotherapy (SABR): Overall Survival Results of the SABR-5 Trial

Abstract 107: The Effects of a Radiation Oncology Emergencies Lecture on Initiation of Care, Timeliness of Consultations Placed, and Duration of Hospitalization


18:15 – 18:45 hs. Mesa de Discusión: Presentación de Caso Clínico

Coordinadora: Dra. Ofelia Pérez Conci (RT)

Panelistas: Dr. Javier Otero (RT), Dr. Alfonso Daza (RT), Dr. Diego Arroyo (RT), Dra. Paola Sánchez (RT)

18:45 – 18:50 hs. Acto de Cierre VII Best of ASTRO

Dr. Jorge Palazzo, Vicepresidente SATRO



El modo más eficiente, flexible, personal **e** inteligente de ganarle al cáncer.

Descubra Ethos™ y adapte los planes de tratamiento todos los días para considerar las variaciones internas diarias en la forma y posición del tumor.

La terapia Ethos es nuestra solución holística y adaptativa, una evolución de la plataforma Halcyon, impulsada por IA, que le permite elegir la opción de tratamiento más adecuada a la anatomía actual del paciente en un intervalo típico de 15 minutos, desde la configuración hasta la administración.

Redefina la forma en que combate el cáncer. Lea más sobre la terapia Ethos en varian.com/ethos hoy mismo.

Información de seguridad: la radiación puede provocar efectos secundarios y no es adecuada para todos los tipos de cáncer. No todos los productos y características están disponibles para todos los mercados.
© 2020 Varian Medical Systems, Inc. Varian es un nombre comercial registrado de Varian Medical Systems, Inc.

varian | **ETHOS™**
A Varian Healthcare Company



Sociedad Argentina de Terapia Radiante Oncológica



SCIENCE OF TODAY
HOPE FOR TOMORROW

Argentina